Australia markets closed

Checkpoint Therapeutics Inc (CZTA.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
1.87500.0000 (0.00%)
As of 08:05AM CET. Market open.
Full screen
Previous close1.8750
Open1.8750
Bid1.8980 x N/A
Ask1.9460 x N/A
Day's range1.8750 - 1.8750
52-week range1.3380 - 3.2700
Volume2,500
Avg. volume40
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Checkpoint Therapeutics Full Year 2023 Earnings: Misses Expectations

    Checkpoint Therapeutics ( NASDAQ:CKPT ) Full Year 2023 Results Key Financial Results Net loss: US$51.8m (loss narrowed...

  • GlobeNewswire

    Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

    WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “We continue to work closely with our third-party contract manufacturing organization to expeditiously resolve the deficiencies noted in t

  • GlobeNewswire

    Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

    WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately. Dr. Sharma currently serves as Vice President of Clinical Development and Therapeutic Head for Nephrology and Hematology at Alexion, AstraZeneca Rare Disease, where he guides